Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma by Cuffel, C.
UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE 
Service d'oto-rhino-laryngologie et chirurgie cervico-faciale, CHUV 
Pattern and clinical significance of cancer-testis gene expression 
in head and neck squamous cell carcinoma 
1 . 
THESE 
préparée sous la direction du Docteur Luc Bron, PD 
et du Professeur Philippe Monnier 
et présentée à la Faculté de biologie et de médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
par 
Cyril CUFFEL 
Médecin diplômé de la Confédération Suisse 
Originaire de Champéry (VS) 
Lausanne 
2012 
Bibliothèque Universitaire 
de Médecine! BiUM 
CHUV-BH08 - Bugnon 46 
CH- îüî i Lausanne 
UNIL 1 Université de Lausanne 
Ecole Doctorale 
Doctorat en médecine 
Imprimatur 
Vu le rapport présenté par le jury d'examen, composé de 
Directeur de thèse 
Co-Directeur de thèse 
Expert 
Directrice de l'Eco le 
doctorale 
Monsieur le Docteur Luc Bron 
Monsieur le Professeur Serg Leyvraz 
Madame le Professeur Stephanie Clarke 
la Conimission MD de l'Ecole doctorale autorise l'impression de la thèse de 
Monsieur Cyril Cuffel 
intitulée 
Analyse du taux d'expression des antigènes associés aux 
tumeurs chez des patients atteints d'un carcinome épidermoïde 
des voies aérodigestives supérieures 
Lausanne, le 17 avril 2012 
pour Le Doyen 
de la Faculté de Biologie et de Médecine 
Madame le Professeur Stephanie Clarke 
Directrice de l'Ecole doctorale 
RAPPORT DE SYNTHESE 
Profil antigénique et caractéristiques cliniques de l'expression d'antigènes tumoraux 
spécifiques dans les cancers ORL : prélude à une vaccination. 
Les cancer-testis antigènes appartiennent à la famille des antigènes tumoraux spécifiques. 
lis ont montré un pouvoir immunogène chez les patients porteurs de différents cancers. En 
effet, ils stimulent sélectivement les lymphocytes cytotoxiques, et leur expression spécifique 
dans les tissus tumoraux en fait une cible idéale pour une vaccination antitumorale. 
Le but de cette étude est d'identifier l'expression de certains de ces antigènes, d'analyser 
leur valeur pronostique et de déterminer la meilleure cible antigénique pour permettre une 
immunothérapie spécifique dans les carcinomes épidermoïdes des voies aérodigestives 
supérieures. 
Le profil et le taux d'expression de 12 cancer-testis antigènes (MAGE-A 1, MAGE-A3, MAGE-
A4, MAGEA10, MAGE-C2, NY-ES0-1, LAGE-1, SSX-2, SSX-4, BAGE, GAGE-1/2, GAGE-
3/4) et de 3 autres antigènes tumoraux spécifiques (PRAME, HERV-K-MEL, NA-17A) ont 
été évalués par RT-PCR sur 57 échantillons de cancers ORL primaires. 
Les paramètres tumoraux et cliniques ont été prospectivement collectés afin de corréler ces 
données avec le résultat de nos investigations immunobiologiques. 
Quatre-vingt-huit pour cent des tumeurs expriment au moins 1 antigène. Une co-expression 
de 3 gènes ou plus est détectée chez 59% des patients. MAGE-A4 (60%), MAGE-A3 (51%), 
PRAME (49%) et HERV-K-MEL (42%) sont les gènes le plus fréquemment exprimés. Ils sont 
totalement absents des muqueuses saines avoisinantes. 
La présence de MAGE-A et NY-ES0-1 à la surface des cellules a été vérifiée par 
immunohistochimie. 
Nos analyses statistiques ont permis d'identifier une diminution de la survie liée au cancer 
chez les patients porteurs d'une tumeur exprimant de multiples cancer-testis antigènes et 
notamment MAGE-A4 dont l'expression indépendante d'autres éléments cliniques s'associe 
statistiquement à un taux de survie diminué. 
Nos résultats ont permis d'identifier un rôle pronostique de l'expression des gènes associés 
aux tumeurs dont l'expression est apparemment liée à un phénotype de malignité plus élevé. 
Cette constatation, corroborée par l'identification parallèle d'un infiltrat lymphocytaire 
spécifique confirme l'utilité potentielle de certains cancer-testis antigènes comme cible pour 
une immunothérapie ciblée dans les carcinomes des voies aérodigestives supérieures. 
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Cancer-testis (Cl) antigens comprise families of tumor-associated antigens that are immunogenic in patients with various 
cancers. Their restricted expression makes them attractive targets for immunotherapy. The aim of this study was to determine 
the expression of several CT genes and evaluate their prognostic value in head and neck squamous cell carcinoma (HNSCC). 
The pattern and level of expression of 12 CT genes (MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, MAGE-C2, NY-ES0-1, LAGE-1, 
SSX-2, SSX-4, BAGE, GAGE-1/2, GAGE-3/4) and the tumor-associated antigen encoding genes PRAME, HERV-K-MEL, and NA-
17A were evaluated by RT-PCR in a panel of 57 primary HNSCC. Over 80% of the tumors expressed at least 1 CT gene. 
Coexpression of three or more genes was detected in 59% of the patients. MAGE-A4 (60%), MAGE-A3 (51%), PRAME (49%) 
and HERV-K-MEL (42%) were the most frequently expressed genes. Overall, the pattern of expression of CT genes indicated a 
coordinate regulation; however there was no correlation between expression of MAGE-A3/A4 and BORIS, a gene whose 
product has been implicated in CT gene activation. The presence of MAGE-A and NY-ES0-1 proteins was verified by 
immunohistochemistry. Analysis of the correlation between mRNA expression of CT genes with ctinico-pathotogical 
characteristics and clinicat outcome reveated that patients with tumors positive for MAGE-A4 or multiple CT gene expression 
had a poorer overall survivat. Furthermore, MAGE-A4 mRNA positivity was prognostic of poor outcome independent of clinicat 
parameters. These findings indicate that expression of CT genes is associated with a more matignant phenotype and suggest 
their usefutness as prognostic markers in HNSCC. 
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The incidence of squamous cell carcinoma of the head and 
neck (HNSCC) is greater than 40,000 new cases per year in 
the United States, and ~soo,ooo cases annually world wide. 
Despite significant advances in early detection and treatment 
of this cancer, the survival rate for patients with HNSCC has 
not changed dramatically over the last decades. The majority 
of patients present with advanced disease and progriosis is 
usually poor. Loco-regional recurrences are the most frequent 
cause of treatment failure even after large resections and ad-
juvant therapy, bath of which carry severe long term morbid-
ity for the patient. Current staging criteria, including TNM 
staging, grading of differentiation, size and site of the neo-
plasm, are not sufficient for predicting outcome. It is there-
fore mandatory to identify new prognostic markers to select 
high-risk patients who may benefit from more aggressive 
therapy and search for navel therapeutic approaches to 
reduce the need for mutilating surgery and morbid adjuvant 
therapy. 
The role of cell mediated immunity against cancer has been 
established for two decades. Numerous antigens coding for im-
munogenic sequences have been identified in different tumor 
types (reviewed in1; a peptide database ofT-cell-defined tumor 
antigens can be found at http://www.cancerimmunity.org/ 
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peptidedatabase/Tcellepitopes.htm), leading to the develop-
ment of new strategies for targeted immunotherapy of can-
cers. Among various classes of tumor associated antigens 
identified, cancer-testis (CT) antigens are particularly interest-
ing targets for specific immunotherapy. CT genes comprise a 
large number of genes or gene families, such as MAGE, 
BAGE, GAGE, SSX, and NY-ES0-1, many of which are 
mapped to chromosome X (X-CT) (reviewed by Simpson 
et al.2). They are expressed by human tumors of different his-
tological types but not by normal somatic tissues, with the 
exception of male germ cells and placenta. Epigenetic mecha-
nisms are at the base of their restricted expression pattern.3•4 
Among the X-linked CT antigens, the MAGE-A family, 
encoded by 12 highly homologous genes, and NY-ES0-1 fam-
ily, consisting ofNY-ES0-1 and LAGE-1, are the best studied 
antigens and have been shown to generate both spontaneous 
and vaccination-induced T-cell mediated responses. In addi-
tion to X-CT gene products, tumor associated proteins like 
PRAME (preferentially expressed antigen on melanoma), 
HERV-K-MEL, a product related to the env-gene of the en-
dogenous human retrovirus K (HERV-K), and NA-17A, the 
product of an alternatively spliced N-acetylglucosaminyltrans-
ferase V mRNA, also contain epitopes recognized by cytolytic 
T cells on tumor cells. 5- 3 
A small number of studies have reported a relatively fre-
quent expression of selected CT genes in HNSCC.9- 13 How-
ever, the small patient number or short follow up time did 
not allow evaluation of their impact of their expression on 
survival. In this study, we investigated the correlation of 
expression of 15 tumor associated antigen-encoding genes, 
including 12 CT genes, in a cohort of HNSCC patients with 
known follow up. The genes were chosen based on the capa-
bility of their products to generate epitopes recognized by 
CDS and/or CD4 T cells. In addition, we sought to determine 
the impact of individual and combined CT gene expression 
on clinical outcome. Our findings show frequent coexpression 
of CT genes in HNSCC of different primary site. Expression 
of MAGE-A4 and coexpression of several CT genes was asso-
ciated with poor overall survival. In addition, Cox regression 
analysis indicated that MAGE-A4 was an independent marker 
of worse outcome in HNSCC. 
Materhd and Methods 
Patients 
Fifty-seven tumor samples from 52 patients treated for pri-
mary HNSCC were prospectively collected at the Department 
of Otolaryngology and Head and Neck surgery of Lausanne 
University Hospital (CHUV), Switzerland. Tumor specimens 
were collected during initial pretherapeutic endoscopy and 
immediately snap-frozen. For 11 patients, samples of nearby 
normal mucosa were collected at the same time. Presence of 
tumor cells was confirmed in each biopsy sample by a stand-
ard haematoxylin-eosin and keratin staining on formalin 
fixed/paraffin embedded material. Tumor site, histological 
grade and clinical stage (according to the 2002 IUCC staging 
Cancer-testis gene expression in HNSCC 
system) were prospectively recorded. Following diagnosis, 
patients were treated by a combination of surgery and che-
moradiotherapy, when required, according to standard inter-
national treatment guidelines. This study was conducted after 
approval by the Research Ethics Committee of Lausanne Uni-
versity and conformed to the 1975 Declaration of Helsinld. 
Ail patients provided informed consent. 
RNA extraction and RT/PCR 
Total RNA was isolated from frozen tissue samples using a 
Nucleospin RNA II kit (Macherey-Nagel) and a Fast-Prep de-
vice (Bio 101 Savant; Savant Instruments). RNA (2 µg) was 
primed with an oligo (dT)i 8 oligonucleotide and reverse-tran-
scribed with MMLV-RT (Invitrogen, Karlsruhe, Germany) 
according to the manufacturer's instructions. Aliquots of 
cDNA corresponding to 100 ng input RNA were used for 
different PCR reactions using a Qiagen Hotstar Taq polymer-
ase Master Kit, except for LAGE-1, NY-ES0-1 and actin PCR, 
performed with Qiagen Taq polymerase (Qiagen GmbH, Hil-
den, Germany). cDNA quality was tested by amplification of 
P-actin in a 21-cycle PCR reaction. The primers, annealing 
temperature and number of cycles performed are described 
in Supporting Information Table Sl. The number of cycles 
chosen for BORIS amplification allowed the detection of a 
1:500 dilution of a testis sample (0.2%), but not background 
transcription (not shown). 14 For amplification, after an initial 
denaturation for 15 min (Hotstar Taq polymerase) or 5 min 
(for other PCR) at 94°C, PCR cycles were performed as fol-
lows: denaturation at 94°C for 1 min, 30 sec at the indicated 
annealing temperature, 1 min at 72°C. A final elongation 
step was performed at 72°C for 10 minutes. Aliquots of each 
reaction were size-fractionated on a 1.5% agarose gel and 
visualized by ethidium bromide staining. Sequence identity of 
representative PCR products was confirmed by automated 
sequencing (Microsynth, Switzerland). RNA from SK-Mel-37 
cells (a gift from Y. T. Chen, New York), a melanoma cell 
line expressing high levels of a broad range of CT genes, and 
NA8-MEL (a gift from F. Jotereau, Nantes, France) was used 
as positive and negative control, respectively. Quantitative 
assessment was performed as previously described, using 1:10 
dilutions of SK-Mel-37 RNA as reference.15 A threshold level 
of CT gene expression by tumor cells appears necessary for 
antigen presentation and recognition by T cells. 15•16 Taldng 
this in consideration, the threshold for sample positivity was 
set at 1 % the expression level of the reference cell line. A tu-
mor "CT score" was calculated by integrating scores of indi-
vidual CT genes (from 0 to 4+) obtained from semiquantita-
tive analyses. Median X-CT antigen score was 6 (mean 8.6). 
Tumors with a "CT score" ?.7 were defined as "high CT 
Score". 
lmmunohistochemistry (IHC) 
Four-micrometer thick serial sections of formalin-fixed, par-
affin-embedded tissue samples were obtained. Expression of 
proteins of the MAGE-A family was assessed using the anti-
lnt. J. Cancer: 128, 2625-2634 (2011) © 2010 UICC 
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pan-MAGE-A antibodies 57B (a gift from G. Spagnoli, Base!, 
Switzerland) and 6Cl. 17 Clone 57B, originally raised against 
MAGE-A3, cross-reacts with several of the homologous 
MAGE-A proteins, and has been reported to primarily detect 
MAGE-A4 in melanoma.17- 19 NY-ES0-1 and LAGE-1 were 
detected with the monoclonal antibody D8.38 (a gift from G. 
Spagnoli). 18•20 Antigen retrieval was performed with micro-
wave treatment in 0.1 M sodium citrate, pH 6.0. Detection 
was performed with the DAKO EnVision™+ system and 
DAB as chromogen (DAKO). Nonimmune mouse IgG was 
used as negative control and sections of testis were used as a 
positive control. Slides were then analyzed by one of the 
authors (W.S.) and by a second independent pathologist as 
control. 
Statistical analyses 
Statistical analysis was performed with STATA 10 software. 
The chi-square test and Fisher's exact test were used to evalu-
ate the associations between CT antigen expression and clin-
ico-pathological features, as appropriate. The Kaplan-Meier 
method was used to estimate overall survival of patients, and 
differences between groups were compared using the log-rank 
test. Multivariate analyses were performed using the Cox pro-
portional hazard mode! to determine the independent contri-
bution of each variable. Covariates with p < 0.08 by univariate 
analysis were entered in the multivariate analysis. Probability 
values ::;0.05 were regarded as significant. In case of multiple 
tumors, a patient was considered CT antigen positive if at least 
one of the tumors analyzed tested positive. 
Results 
Over a period of 19 months, 57 primary HNSCC and 11 
samples of normal mucosa were collected from 52 untreated 
patients (39 male and 13 female). Median age was 61 years 
(range 42-81 years). Table 1 summarizes the clinical and his-
tological characteristics of patients and tumors. Most com-
mon localizations of the primary tumors were oral cavity and 
oropharynx, followed by hypopharynx and larynx. Half of 
the tumors were moderately differentiated. According to 
TNM classification, 11 patients had early stage (i.e. I and II) 
and 41 advanced (i.e. III and IV) cancers. 
Semiquantitative RT/PCR was performed to analyze tumor 
expression of the cancer testis genes MAGE-Al/314/10, 
MAGE-C2, LAGE-1 and NY-ES0-1, SSX-2 and 4, BAGE, 
GAGE-1/2 and 3/4. In addition, we studied the expression of 
the genes coding for the tumor-associated antigens HERV-K-
MEL, PRAME, and NA17. Tumor samples were considered 
as positive when they expressed a given gene at the level of 
at least 1 % that of a reference cell line (see "Material and 
Methods" section). Representative PCR analyses are shown in 
Supporting Information Figure Sl. Frequency of expression 
of various genes in tumors is summarized in Figure la. 
MAGE-A4, MAGE-A3, PRAME, and HERV-K-MEL were the 
most frequently expressed genes and were detected in over 
40% of the samples. MAGE-A3 (51 %) and MAGE-A4 (60%) 
lnt. J. Cancer: 128, 2625-2634 (2011) © 2010 UICC 
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Table 1. Clinico-pathological characteristics of patients and tumors 
studied 
Variable 
Patients (n = 52) 
Sex 
F 
M 
Tu mors (n = 5 7) 
Localization 
Oral cavity 
Oropharynx 
Hypopharynx 
Larynx 
TNM stage 
Tl 
T2 
T3 
T4 
NO 
Nl 
N2 
N3 
Clinicat stage 
Il 
Ill 
IV 
Differentiation grade 
1 (High) 
2 (Moderate) 
3 (Low) 
n 
13 
39 
21 
20 
12 
4 
13 
20 
12 
12 
21 
11 
23 
2 
9 
5 
14 
29 
11 
29 
17 
{%) 
(25) 
(75) 
(37) 
(35) 
(21) 
(7) 
(23) 
(35) 
(21) 
(21) 
(37) 
(19) 
(40) 
(4) 
(15) 
(9) 
(25) 
(51) 
(19) 
(51) 
(30) 
were coexpressed in 35% of tumors, and 75% of tumors 
expressed either gene. MAGE-Al, MAGE-AlO, LAGE-1, SSX-
4, and GAGE were expressed in 16-30% of tumors, while 
other genes had lower expression frequency. BAGE and NA-
17A were detected only in 1 of the 57 tumors analyzed. 
Eighty-nine percent of the tumors showed expression of at 
least one gene in our panel and 81 % expressed at least one 
X-CT gene. Tumors expressed up to 11 of the 12 X-CT genes 
tested. Frequency of coexpression of CT genes on a patient 
basis is shown in Figure lb. Patients had tumors expressing 
an average of 2.9 X-CT and 3.8 tumor associated antigen-
encoding genes. None of the genes tested was expressed in 11 
normal mucosa biopsies collected as controls (not shown). 
CT gene expression is independent of BORIS 
BORIS (Brother of the Regulator of Imprinted Sites), a testis 
specific paralog of the DNA binding protein CTCF, has been 
2628 
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Figure 1. Expression of CT and other genes in HNSCC. (a) 
Frequency of expression of the indicated genes, determined by RT-
PCR, calculated on a tumor basis (n = 57). (b) frequency of 
coexpression of the indicated numbers of genes (in any 
combination) in patients. Light gray, X-CT genes only; dark gray, ail 
genes. 
proposed as a mediator of the induction/derepression of 
other CT genes in Jung cancer cells and dermal fibro-
blasts. 21'22 We therefore analyzed the expression of BORIS, 
itself considered a non-X linked CT gene because of its 
expression pattern, in the HNSCC tumors. BORIS expression 
was detected in 17% of tumors. To visualize the correlation 
between expression of various CT genes and BORIS in indi-
vidual tumors, we grouped the latter into two groups accord-
ing to BORIS expression (Fig. 2) . Within these groups, 
tumors were further ordered according to the number of CT 
genes expressed. A correlation was observed between expres-
sion of the more frequently expressed MAGE-A3 and A4 and 
that of various X-linked CT genes (p < 0.05), but not BORIS 
Cancer-testis gene expression in HNSCC 
(p > 0.2). Expression of BORIS however significantly corre-
lated with expression of multiple CT genes (2:4) and MAGE-
AlO (p < 0.05). Figure 2 also shows that tumors expressing 
multiple CT genes generally displayed also quantitatively 
high expression levels. PRAME, but not HERV-K-MEL, was 
more frequently expressed in tumors expressing multiple CT 
antigens (p < 0.05 and p = 0.81, respectively). 
Expression of MAGE-A and NY-ES0-1 proteins 
To verify that MAGE-A genes are also expressed at the pro-
tein level, RT-PCR positive tumors were analyzed by IHC 
using two anti-panMAGE antibodies (clones 57B and 6Cl). 
Eighty-eight percent (38/43) of MAGE-A3 and/or A4 RT-
PCR positive tumors showed a positive IHC staining with 
antibody 57B. Although heterogeneous, ~3/4 of the tumors 
showed positive staining in over 80% of the cells (not 
shown) . At the cellular level, the staining was both cytoplas-
mic and nuclear, but a nuclear localization was slightly pre-
dominant (not shown). Twenty-one of the 43 tumors tested 
were also positive with clone 6CL Using an antibody that 
recognizes both NY-ES0-1 and LAGE-1, NY-ES0-1 protein 
family was detected in 7 of the 12 NY-ES0-1 and/or LAGE-1 
RT-PCR-positive samples. This staining was predominantly 
cytoplasmic. In five cases the staining was extensive, with 
over 75% positive tumor cells. Examples of immunostainings 
are shown in Figure 3. 
Correlation between expression of CT genes, PRAME, and 
HERV-K-MEL and clinico-pathological parameters 
There was no statistically significant correlation between CT 
gene expression (tested as individual genes, gene combina-
tions, or number of coexpressed genes) and gender, clinical 
stage, tumor localization, differentiation grade, or tumor re-
currence (not shown). One exception was the NY-ES0-1 fam-
ily, which was expressed in moderately and poorly, but not 
well differentiated tumors (p = 0.0345) and more frequently 
in hypopharynx/larynx compared to oral cavity/oropharynx 
(p = 0.014). In addition, MAGE-A4 tended to be preferen-
tially expressed in advanced stage tumors (p = 0.0782). No 
correlation was found between PRAME or HERV-K-MEL 
mRNA positivity and any clinico-pathological parameter. 
Tumor CT gene expression and survival 
The patients in this study had a median follow-up of 27.5 
months (range 1-53, mean 26.4), and overall survival at 4 
years was 52%. Univariate analysis showed that overall sur-
vival significantly correlated with clinical stage, nodal status, 
and tumor stage, but not tumor localization, differentiation 
grade, or sex of the patient (Supporting Information Table 
S2). We investigated the correlation of the mRNA expression 
of various genes, individually or as combinations, with overall 
survival. Patients with MAGE-A4 mRNA positive tumors had 
a significantly poorer outcome compared to those with 
MAGE-A4 mRNA negative tumors (p = 0.0493, Fig. 4). No 
significant correlation was observed between survival and 
lnt. J. Cancer: 128, 2625-2634 (2011) © 2010 UICC 
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. · and other CT enes. Results from semiquantitative RT-PCR are shown color-coded as 
Figure 2. Correlat1on between expression of BORIS g d . d . d·cated in "Material and Methods" section relative 
follows: green, negative; yellow to red, low to high levels, relsp ective:y,ste~::7~~: t:: ~~o~ps according to BORIS expression (negative, left; 
to the reference melanoma cell line SK-Mel-3 7. Tumor samp es arec u 
positive, right) . 
.. 
. . . ~ .... 
.._ #.. I~-..;.;:;.,, , ') • ' 
. h' h . 1 detection of MAGE-A and NY-ES0-1 family proteins in HNSCC. (a) representative staining with anti-MA~E-A Figure 3. lmmuno istoc em1ca . . . asmic and nuclear (b) heterogeneous staining, mainly nuclear, w1th 
antibody 578 . The extensive, heterogeneou_s stam;~ is bot~:~;~1/3/4/10 positive .by ~T-PCR. (c) and (d), staining with anti-NY-ES0-1/ 
~~~~1A~~;~b:~~ibDo8~~8~c;~~~~i~r~ ss:::: i;i;u:: stai~i~r;; D, ar~a with focal staining in a mostly negative tumor. Both tumors were LAGE-
1 positive by RT-PCR. 
positivity for expression of other individual _CT genes (Table 
2 and Fig. 4b, showing survival curve relative to . MAGE-A3 
as example) . Interestingly, curves of patients w1th tumors 
mRNA-positive for NY-ES0-1 family genes leaned towards a 
poorer outcome (p = 0.161). Expression of HER_V-K-MEL 
and PRAME (42 and 49% positive patients, respectlvely) had 
no impact on survival. W e next asked whether expression. of 
multiple X-CT genes (in any combination) or quantitative 
lnt. J. Cancer: 128, 2625-2634 (2011) © 2010 UICC 
high levels of expression (assessed by calc~~ating_ a "CT 
score", as described in "Material and Methods section) had 
an impact on outcome. Coexpression of four or m~re X-CT 
genes (n = 17, 33% patients) did indeed correlate w1~ _a s1g-
nificantly poorer survival (p = 0.045, Fig. 4c). ln addit1~n, a 
high CT score (n = 24, 46%) was associated with 18% differ-
ence in overall survival at 40 months (p = 0.117). Interest-
ingly, patients with tumors negative for ail tested X-CT genes 
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figure 4. Correlation between X-CT gene expression and overall 
survival. Kaplan-Meier survival estimates of patients were 
performed according to RNA expression of (a), MAGE-A4; (b), 
MAGE-A3; (c), multiple X-CT genes (::::4) . (d), survival curves for 
patients with tumors positive or negative for 1 or more X-CT genes. 
Cancer-testis gene expression in HNSCC 
Table 2. Correlation of expression of CT genes with overall survival 
Survival estimates 
4 years 
Variable (%) 
Median 
(months) p-value1 
MAGE-Al 55.4 0.380 
+ 43.8 26.9 
MAGE-A3 56.8 0.406 
+ 48.2 26.9 
MAGE-A4 72.6 0.049 
+ 41.6 24.0 
MAGE-AlO 55.3 0.380 
+ 41.7 26.9 
MAGE-C2 52 .3 0.866 
+ 50.0 
NY-ES0-1 54.4 0.242 
+ 25 .0 26.9 
LAGE-1 53.6 0.378 
+ 44.4 20.3 
SSX-2 51.1 0.523 
+ 66.7 
SSX-4 58.2 0.318 
+ 41.2 23.4 
GAGE-1/2 56.9 0.180 
+ 22.2 20.0 
GAGE-3/4 54.2 0.537 
+ 46.2 26.9 
PRAME 56.7 0.767 
+ 48.5 36.2 
HERV-K-MEL 54 .3 0.464 
+ 48.5 36.2 
:::: i CT No 87.5 0.100 
Yes 46.7 26.9 
::::4 CT No 60.4 0.045 
Yes 35.3 20.0 
High CT score3 No 60.7 0.117 
Yes 41.7 23.4 
MAGE-A3 and/or A4 + No 80.8 0.083 
Yes 45.3 26.9 
NY-ES0-1 and/or LAGE-1 + No 56.4 0.161 
Yes 36.4 20.3 
'Log-rank. p-values ::;a.os are indicated in bold; 2Fifty % survival not 
yet reached ; 3CT gene score (as defined in "Material and Methods" 
section) ?-7. 
(n = 8) had a remarkably good survival, though the log-rank 
test only indicated a trend (p = 0.100, Fig. 4d). We next per-
formed a multivariate Cox regression analysis to assess 
whether CT gene expression was prognostic of poor survival 
independent of clinico-pathological parameters, including 
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clinical and TNM stage. This analysis showed that RT/PCR 
positivity for MAGE-A4 was an independent prognostic indi-
cators in HNSCC (hazard ratio, 2.949; 95% confidence inter-
val 1.085-8.020; p = 0.034) . The association of coexpression 
of four or more X-CT genes with a higher risk of death did 
not persist in the multivariate analysis (hazard ratio, 2.057; 
95% confidence interval 0.919-4.602; p = 0.079) . 
Discussion 
The identification of tumor specific antigens capable of 
inducing a specific immune response has raised interest for 
novel antitumor therapies in various tumor types. CT anti-
gens are amongst the most promising targets for immuno-
therapy. Our finding that CT gene expression confers a 
higher risk of poor outcome in HNSCC further strengthens 
the choice of their products as therapeutic targets in this type 
of cancer. 
We found expression of one or more of the 12 X-CT 
genes tested in 90% and three or more in over 40% of 
HNSCC tumor samples. Overall, ~60% of the patients had 
tumors expressing at least three of the whole panel of genes 
investigated in this study. The X-linked CT genes MAGE-A4, 
MAGE-A3, together with PRAME and HERV-K-MEL, were 
the most frequently expressed. Of the genes studied, only 
four were detected at a frequency below 10%. NY-ES0-1, 
encoding one of the most immunogenic CT antigens, was 
among the latter. However, together with its homolog LAGE-
1, which codes for identical HLA-A2 restricted epitopes, it 
was expressed in approximately a quarter of tumors. The fre-
quencies of expression of individual genes in HNSCC were 
similar to th ose reported in previous studies. 10- 12 Expression 
of MAGE-A and NY-ES0-1 protein families was confirmed 
by IHC staining in the majority of RT-PCR positive tumors. 
Heterogeneous and scattered staining pattern for CT proteins 
has been frequently observed in tumors and could have 
implications for targeted immunotherapy. In this study, most 
tumors showed an extensive staining for both MAGE-A and 
NY-ES0-1 family proteins, indicating that CTA positive cells 
are not rare. Kienstra et al. found that less than half of the 
MAGE-Al and A3 RT-PCR positive tumors were also posi-
tive by immunohistochemistry, however, the antibodies used 
were not specified. 12 Concordant with our results, a recent 
immunohistochemical study has reported the expression of 
MAGE-A (detected by clone 57B) and NY-ES0-1 family pro-
teins in 70% and 30% of pharyngeal tumors, respectively.2 3 
These results are consistent with the relatively high CTA 
expression levels detected by RT-PCR, similar to those 
observed in melanoma. Altogether our study, to our knowl-
edge the larger, in terms of number of genes coding for im-
munogenic products and patients, confirms that a large pro-
portion of patients with HNSCC of different site could 
receive specific immunotherapy targeting multiple antigens. 
Three quarters of the tumors expressed MAGE-A3 and/or 
A4, and expression of other X-linked CT genes was signifi-
cantly correlated with these genes. A similarly coordinated 
lnt. ). Cancer: 128, 2625-2634 (2011) © 2010 UICC 
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expression of CT genes has been reported for nonsmall cell 
lung cancer.24 Interestingly, coexpression of multiple CT 
genes also associated with high mRNA levels (Fig. 2), sug-
gesting that high transcriptional activity is associated with the 
extent of DNA demethylation. The exact mechanism under-
lying this observation is not clear at present. Expression of 
CT genes, especially those encoded in the X-chromosome, is 
strictly confined to germLine and placenta. Methylation of 
CpG islands in CT gene promoters is the primary silencing 
mechanism in healthy somatic tissues. Activation of CT gene 
expression in tumors is thought to result from demethylation 
of these sequences.3'4 BORIS, the product of a CT gene 
located on chromosome 20, has been recently suggested by 
Vatolin et al. as an essential mediator of CT gene derepression, 
particularly MAGE-Al .22 In addition, BORIS has been impli-
cated in NY-ES0-1 expression in lung cancer cells.2 1 In 
HNSSC, the frequency of BORJS expression was only 17% and 
contrasted with the frequent expression of X-linked CT genes. 
As a comparison, a parallel BORJS analysis appLied to meta-
static melanoma samples yielded a frequency of ~50% 
(Rimoldi D., unpublished observation). Expression of CT 
genes, particularly MAGE-A3 and 4, but also MAGE-Al and 
NY-ES0-1, was observed in the absence of BORJS. Conversely, 
BORJS positive tumors did not necessarily express high levels 
of other CT genes. Thus, BORJS expression does not seem to 
be sufficient or necessary for the expression of other CT genes 
in HNSCC, altl10ugh we cannot rule out that a transient 
expression of BORJS may precede their activation. Similar to 
our results, a lack of association between BORJS expression 
and MAGE-Al activation has been reported in cutaneous mel-
anoma, 14 and th us the "gate keeper" for the expression of CT 
genes in these cancers still remains to be identified. 
Overall, we did not find a correlation between expression 
of CT genes, either individually or in combination, and clini-
cal parameters (including TNM staging) or characteristics of 
the primary tumor. This is in agreement with results of most 
previous studies on HNSCC.9' 12 '23 '25 A positive correlation 
between expression of two or more of a panel of nine genes, 
including MAGE-A and NY-ES0-1 families, and higher tu-
mor stage was reported by Figueiredo et al. in a study on 33 
HNSCC patients. 11 There was no correlation in our cohort 
between CT gene expression and tumor or clinical stage, 
except for a marginal association of MAGE-A4 with advanced 
TNM stage. It should be noted however that in our, as well 
as previous HNSCC studies, late stage patients were a major-
ity, thus firm conclusions on correlations with stage await 
results from larger studies. Eura et al (n = 83) found that the 
expression levels of individual MAGE-A genes varied with tu-
mor localization and degree of differentiation, tl10ugh no 
common pattern could be drawn. 10 The only significant cor-
relation of CT gene expression and tumor grade in our 
cohort was the lack of NY-ES0-1 and LAGE-1 in well differ-
entiated tumors. This is at odds with a recent report that 
shows similar expression of these proteins in grade 1 and 2 
pharyngeal tumors, but lower frequency in grade 3 ones.23 
r 
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This discrepancy may be due to the different localizations of 
tumors studied (grade 1 tumors in our study were mostly 
from the oral cavity). A lower frequency of NY-ES0-1 expres-
sion in low histological grade tumors has also been observed 
in urinary tract cancer,26 while the opposite has been 
reported for esophageal cancer.27 Altogether, the correlation 
between differentiation grade and expression of NY-ES0-1 
family genes remains unclear. 
A major finding of this study is the correlation between 
CT gene expression (assessed by RT/PCR) and clinical out-
come. Both MAGE-A4 expression and coexpression of multi-
ple X-linked CT genes (at least 4 of the 12 analyzed) signifi-
cantly correlated with poor survival. More importantly, the 
former emerged as a potential new prognostic indicator. 
These findings further strengthen the choice of CT antigens 
as immunotherapy targets in this type of cancer. A previous 
report on a smaller group of patients found no correlation 
between mRNA expression of CT genes, including the 
MAGE-A family, and tumor recurrence or metastasis, though 
clinical parameters and follow-up were not specified. 11 Our 
study is the first one to evaluate the effect of individual CT 
genes on survival of HNSCC patients. Association of expres-
sion of MAGE-A proteins with a poorer disease-free survival 
in patients with pharyngeal squamous cell carcinoma, has 
been shown in a recent immunohistochemical study, 
although the difference was not statistically significant.23 
While coexpression of multiple X-linked CT genes corre-
lated with poor overall survival, it appears that the different 
genes may not equally contribute to outcome. This was evi-
dent for the MAGE-A family. MAGE-A4 and A3 were 
expressed at similar frequencies, yet only expression of the 
former had an impact on the patients' survival (Figs. 4a and 
4b). This is similar to results by Shigematsu et al.28 showing 
that expression of MAGE-A4, but not MAGE-A3 or NY-ES0-
1, as determined by RT/PCR, was predictive of poor survival 
in nonsmall cell Jung cancer patients.29'30 Gure et al. identi-
fied MAGE-A3 and NY-ES0-1, but not MAGE-A4, as inde-
pendent markers of poor prognosis for adenocarcinoma of 
the lung.24 These discrepancies may be related to the differ-
ent patient populations. Expression of MAGE-A4 protein, as 
detected by antibody 57B, has been reported to be an inde-
pendent marker of poor survival for serous ovarian cancer 
patients31 and to associate with progression of noninvasive 
bladder cancer to muscle invasive tumors.32 Caution however 
must be applied in interpreting positive 57B staining as 
MAGE-A4 positivity, as the antibody can also recognize 
other MAGE-A proteins.17'18 Expression of other CT genes 
has also been generally associated with poor prognosis,24•33·34 
with only few studies revealing a positive effect.27'35 None of 
the CT genes tested in this study was associated with better 
survival. Noteworthy, the small group of patients whose 
tumors tested negative for RNA of ail 12 X-linked CT genes 
tested appeared to have a particularly good outcome, though 
this did not reach statistical significance. The severe progno-
sis of patients with tumors expressing MAGE-A4 or multiple 
Cancer-testis gene expression in HNSCC 
CT genes suggests that these patients may require more 
intense follow-up and aggressive therapy. 
At present, how the expression of MAGE-A4 and other 
CT genes translates into poor clinical outcome can only be a 
subject of speculation. Products of CT genes may confer a 
highly malignant phenotype to the tumor or resistance to 
chemo/radiotherapy. Alternatively, expression of these genes 
may be coinduced with that of others in a subset of tumors 
with a more aggressive behavior. Although the function of 
CT proteins remains poorly understood, different MAGE-A 
proteins have been reported to associate with p53 containing 
complexes and inhibit DNA damage-induced apoptosis, lend-
ing support to the former hypothesis.36-38 However, other 
reports indicated that MAGE-A4 may actually promote apo-
ptosis.39•40 Further studies are clearly needed to establish the 
direct contribution, if any, of MAGE-A4 and other CT gene 
products to a more malignant phenotype in HNSCC. 
In addition to X-linked CT genes, PRAME and HERV-K-
MEL, both coding for in vivo generated CTL epitopes,5·7·8.41.42 
are interesting candidates for specific immunotherapy of 
HNSCC. Because of its restricted expression and its epige-
netic regulation, PRAME, a gene located on chromosome 22 
(reviewed in43.44), is sometimes considered as a non-X-linked 
CT gene (e.g. in CTdatabase, at http://www.cta.lncc.br/). In 
this regard, it is interesting that PRAME expression correlated 
with that of multiple X-linked CT genes in our tumor series. 
The frequency of expression of PRAME in this study (49%) 
confirms frequencies reported in smaller studies (39 and 
42%).8'11 While PRAME expression has been reported as a 
predictor of both poorer and better patient outcome (e.g. in 
breast cancer and promyelocytic leukemia, respec-
tively),34;15'46 it had no influence on survival in our cohort of 
HNSCC patients. We are the first to report the extent of 
HERV-K-MEL expression in a large series of HNSCC tumors. 
HERV-K-MEL is a spliced env sequence from a HERV-K 
pseudogene expressed in over 80% of benign and malignant 
melanocytic lesion.5 Normal tissue expression has been 
reported to be confined to testis and, at a low level, normal 
skin. Spliced env and rec mRNAs from HERV-K genes have 
been detected in other cancers.47 While promoter demethyla-
tion has been implicated in some tumors in the activation of 
related HERV-K sequences,48 the mechanism of activation of 
HERV-K-MEL is not known. ln HNSCC tumors, expression 
of HERV-K-MEL was independent of CT gene expression, 
suggesting that different mechanisms are involved in the acti-
vation of CT genes and endogenous viral sequences. Similar 
conclusions have been drawn in melanoma. As HERV-K 
products can elicit immune responses, they may have biologi-
cal implications in HNSCC. 
In conclusion, this study showed a coordinated activation 
of different CT genes in HNSCC and established an associa-
tion between expression of MAGE-A4 and multiple X-CT 
antigens with poor survival. The value of MAGE-A4 as an in-
dependent prognostic marker should be confirmed in a larger 
prospective study. 
lnt. J. Cancer: 128, 2625-2634 (2011) © 2010 UICC 
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Supplementary Figure 1. Represe~tative ~T-PCR results. Semiquantitative RT-
PCR was performed as described in Matenal and M~t~ods. Tumor samples are 
indicated by numbers. The first three lanes show p~s1t1ve contrais prepared w1th 
serially diluted RNA from the high CT gene expressm~ SK-Mel-37 cells, used as 
reference sample. NA8-MEL cells are CT antigen negat1ve melanoma cells. 
5upplementary Table 51. PCR primers and conditions. 
Gene A"irrers A"irrer Sequence Annealing Cycles 
MAGE-A1 CH014 5'-CGGCCGAAGGAACCTGACCCAG-3' 70°C 30 
CH012 5'-GCTGGAACCCTCACTGGGTIGCG-3' 
MAGE-A3 AB-1197 5'-TGGAGGACCAGAGGCCCCG-3' 68°C 30 
BLE-5 5'-GGAACGA TIATCAGGAGGCCTGG-3' 
MAGE-A4 MAGE-4s 5'-GAGCAGACAGGCCAACCG-3' 68°C 30 
MAGE-4as 5'-AAGGACTCTGCGTCAGGG-3' 
MAGE-A10 MAGE10/3 5'-GGAACCCCTCTITICTACAGAG-3' 55°C 30 
MAGE10/4 5'-TCCTCTGGGGTGCTIGGTA TIA-3' 
NY-ES0-1 ES0-1A 5'-A TGGA TGCTGCAGA TGCGG-3' 60°C 35 
ES0-18 5'-GGCTIAGCGCCTCTGCCCTG-3' 
LAGE-1 BLE-71 5'-CTGGCCACTCGTGCTGGGA-3' 62°C 40 
BLE-72 5'-GCAGGA TGGAAGGTGCCG-3' 
SSX-2 SSX-2A 5'-GTGCTCAAATACCAGAGAAGATG-3' 62°C 35 
SSX-2B 5'-TITIGGGTCCAGA TCTCTCGTG-3' 
SSX-4 SSX-4A 5'-AAA TCGTCTATGTGTATA TGAAGCT-3' 60°C 35 
SSX-4B 5'-GGGTCGCTGATCTCTICATAAAG-3' 1 
MAGE-C2 SL102 5'-AGGCGCGAA TCAAGTIAG-3' 56°C 32 
SL103 5'-CTCCTCTGCTGTGCTGAG-3' 
BAGE BAGE-1 5'-TGGCTCGTCT-CACTCTGG-3' 60°C 30 
BAGE-2 5'-CCTCCTA TIGCTCCTGTIG-3' 
GAGE-1/2 GAGE-1S 5'-GACCAAGACGCTACGTAG-3' 56°C 30 
GAGE-1AS 5'-CCATCAGGACCATCTICA-3' 
GAGE-3/6 GAGE-3S 5'-GACCAAGGCGCTA TGTAG-3' 56°C 30 
GAGE-1AS 5'-CCATCAGGACCATCTICA-3' 
BORIS Boris-a 5'-CAGGCCCTACAAGTGTAACGACTGCAA-3' 62°C 35 
Boris-b 5'-GCA TICGTAAGGCTICTCACCTGAGTG-3' 
PRAME PRAME-1 5'-CTGTACTCA TTICCAGAGCCAGA-3' 62°C 30 
PRAME-2 5'-TA TIGAGAGGGTTICCAAGGGGTI-3' 
HERV-K-MEL OFC 646 5'-TGCAGAGGA TATAAGGAGAT-3' 60°C 40 
OFC600 5'-GGATCAAACTGCAAGGCA-3' 
NA-17A NA17-1 5'-GA TGTGTICA TACGCTGTGTGGT-3' 62°C 30 
NA17-2 5'-CTCTACTICCTCCTGA TIGTIGAG-3' 
A clin CH015 5'-GGCA TCGTGA TGGACTCCG-3' 55°C 21 
CH016 5'-GCTGGAAGGTGGACAGCGA-3' 
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5upplementary Table 52. Correlation of clinico-pathological parameters with overall 
survival. 
5urvival estimates 
Variable 4 years (%) Median (months) P-valuea 
Sex F 75.0 0.061 
M 44.5 26.9 
Localization Oral cavity 68.4 0.117 
Oropharynx 41 .2 20.0 
Hypopharynx 28.3 23.4 
Larynx 75.0 
Grade 1 90 .0 0.061 
2 38 .5 24 .0 
3 51.3 
Clinical stage 1111 80.1 0.011 
Ill 69 .2 
IV 32 .5 18.3 
T-stage 1/2 66 .9 0.020 
3/4 35 .8 23.4 
N-stage 0 71.8 0.018 
1 70 .0 
>1 28.4 18.3 
a Log-rank. P-values $ 0.05 are indicated in bold 
bFifty % survival not yet reached . 
